Australian Group on Antimicrobial Resistance Hospital-onset Staphylococcus aureus Surveillance Programme annual report, 2011
dc.contributor.author | Coombs, Geoffrey | |
dc.contributor.author | Nimmo, G. | |
dc.contributor.author | Pearson, J. | |
dc.contributor.author | Collignon, P. | |
dc.contributor.author | Bell, J. | |
dc.contributor.author | McLaws, M. | |
dc.contributor.author | Christiansen, K. | |
dc.contributor.author | Turnidge, J. | |
dc.date.accessioned | 2017-01-30T10:55:24Z | |
dc.date.available | 2017-01-30T10:55:24Z | |
dc.date.created | 2015-10-29T04:09:56Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | Coombs, G. and Nimmo, G. and Pearson, J. and Collignon, P. and Bell, J. and McLaws, M. and Christiansen, K. et al. 2013. Australian Group on Antimicrobial Resistance Hospital-onset Staphylococcus aureus Surveillance Programme annual report, 2011. Communicable Diseases Intelligence Quarterly Report. 37 (3): pp. E210-E218. | |
dc.identifier.uri | http://hdl.handle.net/20.500.11937/6761 | |
dc.description.abstract |
In 2011, the Australian Group on Antimicrobial Resistance (AGAR) conducted a period-prevalence survey of clinical Staphylococcus aureus isolated from hospital inpatients. Twenty-nine microbiology laboratories from all states and mainland territories participated. Specimens were collected more than 48 hours post-admission. Isolates were tested by Vitek2® antimicrobial susceptibility card (AST-P612 card). Nationally, the proportion of S. aureus that were methicillin-resistant S. aureus (MRSA) was 30.3%; ranging from 19.9% in Western Australia to 36.8% in New South Wales/Australian Capital Territory. Resistance to the non-ß-lactam antimicrobials was common except for rifampicin, fusidic acid, high-level mupirocin and daptomycin. No resistance was detected for vancomycin, teicoplanin or linezolid. Antibiotic resistance in methicillin susceptible S. aureus (MSSA) was rare apart from erythromycin (13.2%) and there was no resistance to vancomycin, teicoplanin or linezolid. Inducible clindamycin resistance was the norm for erythromycin resistant, clindamycin intermediate/susceptible S. aureus in Australia with 90.6% of MRSA and 83.1% of MSSA with this phenotype having a positive double disc diffusion test (D-test). The proportion of S. aureus characterised as being healthcare-associated MRSA (HA-MRSA) was 18.2%, ranging from 4.5% in Western Australia to 28.0% in New South Wales/Australian Capital Territory. Four HA-MRSA clones were characterised and 98.8% of HA-MRSA isolates were classified as either ST22-IV [2B] (EMRSA-15) or ST239-III [3A] (Aus-2/3 EMRSA). Multiclonal community-associated MRSA (CA-MRSA) accounted for 11.7% of all S. aureus. In Australia, regional variation in resistance is due to the differential distribution of MRSA clones between regions, particularly for the major HA-MRSA clone, ST239-III [3A] (Aus-2/3 EMRSA), which is resistant to multiple non-ß-lactam antimicrobials. | |
dc.title | Australian Group on Antimicrobial Resistance Hospital-onset Staphylococcus aureus Surveillance Programme annual report, 2011 | |
dc.type | Journal Article | |
dcterms.source.volume | 37 | |
dcterms.source.number | 3 | |
dcterms.source.startPage | E210 | |
dcterms.source.endPage | E218 | |
dcterms.source.issn | 1447-4514 | |
dcterms.source.title | Communicable diseases intelligence quarterly report | |
curtin.department | School of Biomedical Sciences | |
curtin.accessStatus | Fulltext not available |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |